| Date | Title | Description |
| 04.06.2025 | Akadeum Life Sciences Raises $20M+ in Funding | Akadeum Life Sciences, an Ann Arbor, MI-based company which specializes in buoyancy-based cell separation technology, raised $20M+ in funding.
The round was led by Michigan Capital Network, with participation from Arboretum Ventures, NYBC V... |
| 19.06.2024 | ElevateBio: компания по производству генетических лекарств | Содержание
История компании
Технологии: объединение производства и некстген технологий терапевтического производства
Экосистема компании
BaseCamp
Партнеры
Отраслевые партнерства
Академические партнерства
Привлечение инвестиций История компа... |
| 05.02.2024 | Startup funding is falling in most major cities. So why is Boston pulling ahead? | Startups Startup funding is falling in most major cities. So why is Boston pulling ahead?
Melia Russell and Rebecca Torrence
2024-02-05T19:43:19Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The letter F.
Facebook Email ic... |
| 26.10.2023 | Despite one of biotech's biggest fundraisings of the year, ElevateBio cuts 13% of staff | Even with $401 million in the bank—thanks to one of the year’s largest biotech fundraisings—ElevateBio is still shaving off some preclinical work resulting in layoffs that will affect 13% of the workforce.
“ElevateBio is in a position of st... |
| 25.05.2023 | ElevateBio raises $401 million in year's largest biotech VC deal | ElevateBio, a Massachusetts-based developer of cell and gene therapies, raised $401 million in Series D funding led by existing investor Matrix Capital Management.
Why it matters: This is the year's largest biotech VC deal, topping the mark... |
| 24.05.2023 | SoftBank-backed biotech research firm ElevateBio raises $401m funding | ElevateBio said on Wednesday it had raised $401 million in a new funding round led by a fund run by Matrix Capital Management, as the venture capital market looks to stage a rebound following a dreary 2022.
The biotechnology research firm h... |
| 24.05.2023 | ElevateBio Lands $401M Series D |
WALTHAM, MA, ElevateBio announced the closing of its $401 million Series D financing led by the AyurMaya Capital Management Fund.
>> Click here for more funding data on ElevateBio
>> To export ElevateBio funding data to PDF ... |
| 24.05.2023 | ElevateBio Raises $401M in Series D Financing | ElevateBio, a Waltham, MA-based technology company focused on powering the creation of life-transforming cell and gene therapies, raised $401M in Series D funding.
The round was led by AyurMaya Capital Management Fund, managed by Matrix Cap... |
| 18.04.2022 | Biotech's top 10 money raisers of 2021 | After a bustling, record-setting 2020 for private biotechs raising cash, the bar heading into 2021 was exceptionally high. Turns out, private investors elected to just take the bar and do pull-ups, breaking 2020’s record by a whopping 26%.
... |
| 17.12.2021 | The $100M+ Dollar Club of U.S. Startups: Massachusetts | Officially known as the Commonwealth of Massachusetts, the state is located in the North-Eastern part of the U.S. and spans an area of 10,554 sq. mi (27,336 sq. km). Massachusetts shares its border with New Hampshire, Rhode Island, Connecti... |
| 18.03.2021 | ElevateBio Announces Chief Scientific Officer of Regenerative Medicine, Melissa Carpenter, PhD, Elected to the International Society for Stem Cell Research Board of Directors | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 18, 2021--
ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that the company’s Chief Scientific Officer of Regenerative... |
| 16.03.2021 | ElevateBio collects $525M Series C | ElevateBio has raised $525 million in a round led by Matrix Capital Management, with participation from investors including SoftBank's Vision Fund 2 and Fidelity Management & Research. Based in Massachusetts, the company is a developer ... |
| 16.03.2021 | ElevateBio Raises $525 Million Series C Funding to Scale Scales Disruptive Cell and Gene Therapy Business Model | – Proceeds to support the acceleration and scaling of ElevateBio’s end-to-end cell and gene therapy technology platform offering
– Series C financing led by Matrix Capital Management, joined by additional new investors SoftBank Vision Fund ... |
| 16.03.2021 | ElevateBio Elevates with $525M Series C Funding |
CAMBRIDGE, MA, ElevateBio has raised $525 million in a Series C financing led by Matrix Capital Management.
>> Click here for more funding data on ElevateBio
>> To export ElevateBio funding data to PDF and Excel, click here
... |
| 15.03.2021 | Daily funding roundup - March 15th, 2021 | Stripe landed $600M; ElevateBio raised $525M; Graphite Bio secured $150M
Airtable: Airtable is a San Francisco-based no-code relational database that has amassed a customer base that spans 250,000 different organizations. Airtable just clos... |
| 15.03.2021 | SOFTBANK GROUP CORP.
ElevateBio raises $525 million in funding from SoftBank, others | March 15 (Reuters) - ElevateBio said on Monday it has raised $525 million in new funding led by Matrix Capital Management, to help increase manufacturing capacity and also advance development of its cell and gene therapies.
The new financin... |
| 15.03.2021 | ElevateBio nets $525M to bolster cell, gene therapy platform | After launching multiple companies and signing some partners, ElevateBio is grabbing another $525 million to fuel its work in cell and gene therapy. The funds will bolster its technology and manufacturing capacity and bankroll more partners... |
| 15.03.2021 | ElevateBio nets $525M to bolster cell, gene therapy platform | After launching multiple companies and signing some partners, ElevateBio is grabbing another $525 million to fuel its work in cell and gene therapy. The funds will bolster its technology and manufacturing capacity and bankroll more partners... |
| 15.03.2021 | ElevateBio : Scales Disruptive Cell and Gene Therapy Business Model with $525 Million Series C Financing | ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced it has raised $525 million in a Series C financing. ElevateBio has created a new disruptive business model ad... |
| 15.03.2021 | ElevateBio Raises $525 Million for Cell, Gene Therapies | ElevateBio LLC has raised a $525 million venture-capital financing to expand its ability to help corporate partners develop cell and gene therapies, and to build its own portfolio of disease treatments.
Drugmakers are creating cell and gene... |
| 15.03.2021 | ElevateBio raises $525M to advance its cell and gene therapy technologies | ElevateBio, one of the leading biotech companies focused on gene-based therapies, has raised a massive $525 million Series C round of financing, more than doubling the company’s $193 million Series B funding which closed last year. This new... |
| 15.03.2021 | ElevateBio Raises $525M for Cell and Gene-Based Therapy Research | Photo: Shutterstock
ElevateBio, a Cambridge-based biotech company focused on cell and gene-based therapies, announced Monday it closed on a massive $525 million Series C led by Matrix Capital, with participation from new investors SoftBank ... |
| 15.03.2021 | ElevateBio Raises $525M in Series C Financing | ElevateBio, a Cambridge, Mass.-based cell and gene therapy technology company focused on advancing new cell and gene therapies, raised $525m in Series C financing.
The round was led by Matrix Capital Management with participation from new ... |
| 31.03.2020 | ElevateBio Closes $170 Million Series B Financing | - |
| 30.03.2020 | ElevateBio Closes $170 Million Series B Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--ElevateBio, LLC, a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies, today announced it has closed a $170-million Series B financing that will support and a... |
| 30.03.2020 | ElevateBio Raises $170M in Series B Financing | ElevateBio, LLC, a Waltham, Mass. – based creator and operator of a portfolio of innovative cell and gene therapy companies, closed a $170m Series B financing.
New investors The Invus Group, Surveyor Capital (A Citadel company), EDBI, and V... |
| 30.03.2020 | Cell and gene therapy startup ElevateBio raises $170M | While economic conditions and the ongoing global coronavirus pandemic may not make for the best atmosphere for raising funding, some companies are still announcing round closures with significant money committed. Cambridge-based ElevateBio,... |
| 30.03.2020 | ElevateBio Raises $170M for Next-Gen Cell and Gene Therapy Research | Image: Shutterstock
On Monday, Cambridge biotech startup ElevateBio announced the closing of its $170 million Series B funding round. This new investment will help fund the company’s next stage of growth as it continues its research into ce... |
| 30.03.2020 | ElevateBio Closes $170M Series B Financing |
CAMBRIDGE, MA, ElevateBio has closed a $170-million Series B financing.
>> Click here for more funding data on ElevateBio
>> To export ElevateBio funding data to PDF and Excel, click here
ElevateBio, LLC, a Cambridge-base... |
| 30.05.2019 | Houston biotech company closes $120M Series B, Chevron taps local startup for program, and more innovation news | Big things are happening in Houston — from a $120 million close to the U.S. Department of Energy picking a Houston-area company for nuclear energy research. Here are the highlights of Houston innovation news you might have missed.
Need more... |
| 22.05.2019 | Biotech builder ElevateBio reveals its first portfolio company: AlloVir | ElevateBio launched just last week with $150 million to build cell and gene therapy companies. Now, it’s unveiling its first portfolio company: AlloVir, a biotech working on off-the-shelf T-cell therapies against several common viruses, inc... |
| 14.05.2019 | Term Sheet — Tuesday, May 14 | THE BLAME GAME
As of Monday’s market close, those who bought into Uber at its IPO were down roughly $1.4 billion. Eesh.
Paid Content You can't secure what you can't see From ExtraHop
There’s been a deluge of criticism around Morgan Stanley’... |
| 13.05.2019 | ElevateBio launches with $150M Series A – to launch cell and gene therapy companies | “ElevateBio is uniquely structured to leverage our cell and gene therapy company-building capabilities to accelerate the development, manufacturing and delivery of highly innovative therapies across a growing number of portfolio companies,”... |
| 13.05.2019 | ElevateBio Launches with $150M Series A |
CAMBRIDGE, MA, ElevateBio has closed $150 million in Series A financing.
>> Click here for more funding data on ElevateBio
>> To export ElevateBio funding data to PDF and Excel, click here
ElevateBio, a Cambridge-based bi... |
| - | Healthcare startups netted a record number of mega-deals last quarter. Meet the 10 companies pulling in the most cash. | A KRY physician examines a patient. KRY This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Investors poured $14.6 billion into healthcare startups during the first quarter of 2020.
Digital h... |
| - | ElevateBio Scales Disruptive Cell and Gene Therapy Business Model with $525 Million Series C Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 15, 2021--
ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced it has raised $525 million in a Series C financing. Elevate... |
| - | ElevateBio launches with $150M Series A – to launch cell and gene therapy companies | A new firm aims to take cell and gene therapy projects from scientific researchers and turn them into new companies.
Cambridge, Massachusetts-based ElevateBio announced its launch Monday with $150 million in Series A funding. The round was ... |
| - | «Disruptor 50» от CNBC — самые быстроразвивающиеся компании | «Disruptor 50» от CNBC — самые быстроразвивающиеся компании
29 Мая, 2021, 12:01
Даниил Ивженко
1228
CNBC представила свой девятый ежегодный список «2021 Disruptor 50», в котором собраны частные компании, выходящие из пандемии с быстрым темп... |
| - | ElevateBio | “We provide the tools, time, and environment to innovate and accelerate development of life-saving Cell and gene therapies. Cell and gene therapy innovation.” |
